



SUVEN Life Sciences

Communication to investors **June 2015**

14-Aug-15

2015-16 Q1 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter1 – June 2015

(Quarter on Quarter)




MAJOR PROFITABILITY RATIOS



	Q1 Jun 15-16	Q4 Mar 14-15
PAT to Income	19.08%	14.81%
Cash Flow to Income	21.81%	17.14%
EBIDTA to Income	28.39%	23.17%
Pre-R&D EBITDA to Income	43.42%	36.60%




INCOME COMPARISON






PROFIT COMPARISON






EBIDTA COMPARISON






R & D – EXPENDITURE





PRE-R&D EBIDTA




14-Aug-15

2015-16 Q1 results



PRE-R&D CASHFLOW





Updates for the quarter

- SUVN-502 - Completed phase 1b clinical trial under US-IND; in preparation for Phase 2a (POC) study on 537 patients in USA
- SUVN-G3031 - Completed SAD and MAD studies of phase 1 clinical trial under US-IND
- SUVN-D4010 – IND filed in USA
- Number of active CRAMS projects - $111+3=114$
- Suven has 753 product patents for 26 inventions and 37 process patents for 7 inventions